Opportunity for a License: Assay To Screen Inhibitors of HIV-1 Aspartyl Protease

الملخص

The National Institutes of Health desires to license (in accordance with 35 U.S.C. 207) a novel radiometric assay system for identifying potential new anti-retroviral drugs that target HIV-1 aspartyl proteinase. This retroviral proteinase processes viral proteins and permits their assembly into the structural components of the infectious HIV-1 virions. If this enzyme activity can be inhibited, no mature infectious viral particles are produced.